Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers


  Free Subscription


1 Acta Haematol
2 Am J Hematol
2 Ann Hematol
4 Blood
2 Bone Marrow Transplant
29 Br J Haematol
1 Cancer Chemother Pharmacol
1 Cancer Res
1 Eur J Haematol
1 Exp Hematol
4 Leuk Lymphoma
3 Leuk Res
2 Leukemia
1 N Engl J Med
2 PLoS One

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Acta Haematol

  1. YANG S, Zhu R, Li N, Feng Y, et al
    Ibrutinib in Advanced Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Lower Risk of Hepatitis B Virus Reactivation.
    Acta Haematol. 2021 Sep 20:1-9. doi: 10.1159/000518398.
    PubMed         Abstract available

    Am J Hematol

  2. FURSTENAU M, Giza A, Stumpf T, Robrecht S, et al
    Second primary malignancies in treated and untreated patients with chronic lymphocytic leukemia.
    Am J Hematol. 2021 Sep 30. doi: 10.1002/ajh.26363.

  3. GRIMM J, Jentzsch M, Bill M, Backhaus D, et al
    Clinical implications of SRSF2 mutations in AML patients undergoing allogeneic stem cell transplantation.
    Am J Hematol. 2021;96:1287-1294.
    PubMed         Abstract available

    Ann Hematol

  4. KIM TH, Choi YW, Ahn MS, Choi YS, et al
    Early removal of central venous catheter may not impact the in-hospital mortality in patients with acute leukemia.
    Ann Hematol. 2021 Sep 30. pii: 10.1007/s00277-021-04673.
    PubMed         Abstract available

  5. ZHAO P, Ni M, Ma D, Fang Q, et al
    Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2021 Sep 27. pii: 10.1007/s00277-021-04674.
    PubMed         Abstract available


  6. STEIN EM, DiNardo CD, Fathi AT, Mims AS, et al
    Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
    Blood. 2021;137:1792-1803.
    PubMed         Abstract available

  7. SCHWAB C, Roberts K, Boer JM, Gohring G, et al
    SSBP2-CSF1R is a recurrent fusion in B-lineage acute lymphoblastic leukemia with diverse genetic presentation and variable outcome.
    Blood. 2021;137:1835-1838.

  8. SOARES F, Chen B, Lee JB, Ahmed M, et al
    CRISPR screen identifies genes that sensitize AML cells to double-negative T-cell therapy.
    Blood. 2021;137:2171-2181.
    PubMed         Abstract available

  9. ALEJO-VALLE O, Weigert K, Bhayadia R, Ng M, et al
    The megakaryocytic transcription factor ARID3A suppresses leukemia pathogenesis.
    Blood. 2021 Sep 27. pii: 477055. doi: 10.1182/blood.2021012231.
    PubMed         Abstract available

    Bone Marrow Transplant

  10. JIMENEZ JIMENEZ AM, De Lima M, Komanduri KV, Wang TP, et al
    An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis.
    Bone Marrow Transplant. 2021 Sep 28. pii: 10.1038/s41409-021-01450.
    PubMed         Abstract available

  11. HU K, Wang Y, Teng X, Hu Y, et al
    Cell subsets and cytokine dynamics in cerebrospinal fluid after CAR-T cell therapy for B-cell acute lymphoblastic leukemia with central nervous system involvement.
    Bone Marrow Transplant. 2021 Sep 27. pii: 10.1038/s41409-021-01471.

    Br J Haematol

  12. SMOLEJ L, Brychtova Y, Cmunt E, Doubek M, et al
    Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL St
    Br J Haematol. 2021 Feb 22. doi: 10.1111/bjh.17373.
    PubMed         Abstract available

  13. SEMBILL S, Gohring G, Schirmer E, Lutterloh F, et al
    Paediatric chronic myeloid leukaemia presenting in de novo or secondary blast phase - a comparison of clinical and genetic characteristics.
    Br J Haematol. 2021;193:613-618.
    PubMed         Abstract available

  14. DANDER E, Fallati A, Gulic T, Pagni F, et al
    Monocyte-macrophage polarization and recruitment pathways in the tumour microenvironment of B-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2021;193:1157-1171.
    PubMed         Abstract available

  15. MIKHAILOVA E, Semchenkova A, Illarionova O, Kashpor S, et al
    Relative expansion of CD19-negative very-early normal B-cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR-T cell therapy: implications for flow cytometric detection of minimal residual disease.
    Br J Haematol. 2021;193:602-612.
    PubMed         Abstract available

  16. CREUZET E, Nourrisson C, Chaleteix C, Poirier P, et al
    Cerebral aspergillosis in a patient on ibrutinib therapy.
    Br J Haematol. 2021;193:1025.

  17. DE MIGUEL SANCHEZ C, Robles de Castro D, Pison Herrero C, Perez Persona E, et al
    Primary plasma cell leukaemia presenting with flower-shaped nuclei.
    Br J Haematol. 2021;193:689.

  18. TSAUR G, Popov A, Riger T, Kustanovich A, et al
    Prognostic value of minimal residual disease measured by fusion-gene transcript in infants with KMT2A-rearranged acute lymphoblastic leukaemia treated according to the MLL-Baby protocol.
    Br J Haematol. 2021;193:1151-1156.
    PubMed         Abstract available

  19. BRIVIO E, Chantrain CF, Gruber TA, Thano A, et al
    Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series.
    Br J Haematol. 2021;193:1172-1177.
    PubMed         Abstract available

  20. CHEN D, Chen W
    Salmon-coloured granules in residual acute myeloid leukaemia with t(8;21)(q22;q22.1); RUNX1-RUNX1T1.
    Br J Haematol. 2021;193:691.

  21. NOY-LOTAN S, Krasnov T, Dgany O, Jeison M, et al
    Incorporation of somatic panels for the detection of haematopoietic transformation in children and young adults with leukaemia predisposition syndromes and with acquired cytopenias.
    Br J Haematol. 2021;193:570-580.
    PubMed         Abstract available

  22. HJORT JAKOBSEN L, Stidsholt Roug A, Kiesbye Ovlisen A, Werenberg Marcher C, et al
    Temporal changes in survival among adult patients with acute myeloid leukaemia in the period 2000-2016: a Danish population-based study.
    Br J Haematol. 2021;193:482-487.
    PubMed         Abstract available

  23. SMOLEJ L
    Skipping a step: what happened to the design of randomized clinical trials in chronic lymphocytic leukaemia?
    Br J Haematol. 2021;193:723-726.
    PubMed         Abstract available

  24. BRAS AE, Osmani Z, de Haas V, Jongen-Lavrencic M, et al
    Standardised immunophenotypic analysis of myeloperoxidase in acute leukaemia.
    Br J Haematol. 2021;193:922-927.
    PubMed         Abstract available

  25. WANG H, Zhou Y, Huang X, Zhang Y, et al
    Minimal residual disease level determined by flow cytometry provides reliable risk stratification in adults with T-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2021;193:1096-1104.
    PubMed         Abstract available

  26. FLYGT H, Sandin F, Dahlen T, Dremaine A, et al
    Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry.
    Br J Haematol. 2021;193:915-921.
    PubMed         Abstract available

  27. SHAH MV, Saliba RM, Varma A, Ciurea SO, et al
    Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era.
    Br J Haematol. 2021;193:1004-1008.

  28. CHOWDHURY O, Bruguier H, Mallett G, Sousos N, et al
    Impaired antibody response to COVID-19 vaccination in patients with chronic myeloid neoplasms.
    Br J Haematol. 2021;194:1010-1015.

  29. HARRINGTON P, Doores KJ, Radia D, O'Reilly A, et al
    Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia.
    Br J Haematol. 2021;194:999-1006.
    PubMed         Abstract available

  30. KARANTANOS T, Gondek LP, Varadhan R, Moliterno AR, et al
    Gender-related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
    Br J Haematol. 2021;193:1142-1150.
    PubMed         Abstract available

  31. XU R, Huang X, Li C, Deng C, et al
    Bone marrow mesenchymal stromal cells in chronic myelomonocytic leukaemia: overactivated WNT/beta-catenin signalling by parallel RNA sequencing and dysfunctional phenotypes.
    Br J Haematol. 2021;193:928-940.
    PubMed         Abstract available

  32. MOSKORZ W, Cosmovici C, Jager PS, Cadeddu RP, et al
    Myelodysplastic syndrome patients display alterations in their immune status reflected by increased PD-L1-expressing stem cells and highly dynamic exhausted T-cell frequencies.
    Br J Haematol. 2021;193:941-945.
    PubMed         Abstract available

  33. CAO H, Neerincx A, de Bono B, Lakner U, et al
    Sialic acid-binding immunoglobulin-like lectin (Sigelac)-15 is a rapidly internalised cell-surface antigen expressed by acute myeloid leukaemia cells.
    Br J Haematol. 2021;193:946-950.
    PubMed         Abstract available

  34. DHOLARIA B, Savani BN, Huang XJ, Nagler A, et al
    The evolving role of allogeneic haematopoietic cell transplantation in the era of chimaeric antigen receptor T-cell therapy.
    Br J Haematol. 2021;193:1060-1075.
    PubMed         Abstract available

  35. KIM DDH, Novitzky-Basso I, Kim TS, Atenafu EG, et al
    Optimal duration of imatinib treatment/deep molecular response for treatment-free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial.
    Br J Haematol. 2021;193:779-791.
    PubMed         Abstract available

  36. NISHIMURA A, Naruto T, Miyamoto S, Grigg A, et al
    Genomics analysis of leukaemia predisposition in X-linked agammaglobulinaemia.
    Br J Haematol. 2021;193:1277-1281.

  37. DO C, Best OG, Thurgood L, Hotinski A, et al
    Insight into del17p low-frequency subclones in chronic lymphocytic leukaemia (CLL): data from the Australasian Leukaemia and Lymphoma Group (ALLG)/CLL Australian Research Consortium (CLLARC) CLL5 trial.
    Br J Haematol. 2021 Apr 13. doi: 10.1111/bjh.17394.
    PubMed         Abstract available

  38. KHARFAN-DABAJA MA, Labopin M, Brissot E, Kroger N, et al
    Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia.
    Br J Haematol. 2021;193:592-601.
    PubMed         Abstract available

  39. AOKI K, Kurashige M, Ichii M, Higaki K, et al
    Identification of CXCL12-abundant reticular cells in human adult bone marrow.
    Br J Haematol. 2021;193:659-668.
    PubMed         Abstract available

  40. VAN DE GEER A, Zandstra J, Tanck MWT, Nur E, et al
    Biomarkers to predict infection and infection-related complications during chemotherapy-induced neutropenia in acute myeloid leukaemia: a pilot study.
    Br J Haematol. 2021;193:1008-1012.

    Cancer Chemother Pharmacol

  41. CONDORELLI A, Matteo C, Leotta S, Schinina G, et al
    Venetoclax penetrates in cerebrospinal fluid of an acute myeloid leukemia patient with leptomeningeal involvement.
    Cancer Chemother Pharmacol. 2021 Sep 29. pii: 10.1007/s00280-021-04356.
    PubMed         Abstract available

    Cancer Res

  42. SANJIV K, Calderon-Montano JM, Pham TM, Erkers T, et al
    MTH1 inhibitor TH1579 induces oxidative DNA damage and mitotic arrest in acute myeloid leukemia.
    Cancer Res. 2021 Sep 30. pii: 0008-5472.CAN-21-0061.
    PubMed         Abstract available

    Eur J Haematol

  43. KRISTJANSDOTTIR ER, Toksvang LN, Schmiegelow K, Rank CU, et al
    Prevalence of non-adherence and non-compliance during maintenance therapy in adults with acute lymphoblastic leukemia and their associations with survival.
    Eur J Haematol. 2021 Sep 25. doi: 10.1111/ejh.13711.
    PubMed         Abstract available

    Exp Hematol

  44. TREMBLAY CS, Ting SB, McCluskey A, Robinson PJ, et al
    Shutting the gate: targeting endocytosis in acute leukemia.
    Exp Hematol. 2021 Sep 23. pii: S0301-472X(21)00326.

    Leuk Lymphoma

  45. LEE Y, Yun J, Jeong D, Ryu S, et al
    Genetic profile of primary plasma cell leukemia in Korea: comparison with plasma cell myeloma.
    Leuk Lymphoma. 2021 Oct 1:1-10. doi: 10.1080/10428194.2021.1983568.
    PubMed         Abstract available

  46. VAN BESIEN K, Gomez-Arteaga A
    Maintenance therapy after allogeneic transplant for acute myeloid leukemia: great expectations.
    Leuk Lymphoma. 2021 Sep 29:1-4. doi: 10.1080/10428194.2021.1980787.

  47. MALPICA L, Castro D, Enriquez DJ, Oviedo-Pecho R, et al
    An international, multicenter, retrospective study on the positive impact of cutaneous involvement on the clinical outcome of adult T-cell leukemia/lymphoma.
    Leuk Lymphoma. 2021 Sep 29:1-11. doi: 10.1080/10428194.2021.1984455.
    PubMed         Abstract available

  48. CHAJUWAN T, Kansuwan P, Kobbuaklee S, Chanswangphuwana C, et al
    Characteristics and clinical correlation of TIM-3 and PD-1/PD-L1 expressions in leukemic cells and tumor microenvironment in newly diagnosed acute myeloid leukemia.
    Leuk Lymphoma. 2021 Sep 29:1-7. doi: 10.1080/10428194.2021.1984454.
    PubMed         Abstract available

    Leuk Res

  49. DU X, Liu H, Yang C, Shi X, et al
    LncRNA landscape analysis identified LncRNA LEF-AS1 as an oncogene that upregulates LEF1 and promotes survival in chronic lymphocytic leukemia.
    Leuk Res. 2021;110:106706.
    PubMed         Abstract available

  50. CARRAWAY HE, Sawalha Y, Gojo I, Lee MJ, et al
    Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukem
    Leuk Res. 2021;110:106707.
    PubMed         Abstract available

  51. GOKCEN S, Bagriacik EU, Kayhan H, Yagci M, et al
    Immunomolecular evaluation of dihydroartemisinin effects on apoptosis in chronic lymphocytic leukemia cell lines.
    Leuk Res. 2021;110:106702.
    PubMed         Abstract available


  52. SUD A, Law PJ, Houlston RS
    The clinical utility of polygenic risk scores for chronic lymphocytic leukemia.
    Leukemia. 2021 Sep 25. pii: 10.1038/s41375-021-01429.

  53. BLIXT L, Bogdanovic G, Buggert M, Gao Y, et al
    Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients.
    Leukemia. 2021 Sep 25. pii: 10.1038/s41375-021-01424.
    PubMed         Abstract available

    N Engl J Med

  54. BARRY D, Schmieder A
    Leukemia Cutis.
    N Engl J Med. 2021;385:1316.

    PLoS One

  55. LUONG A, Cerignoli F, Abassi Y, Heisterkamp N, et al
    Analysis of acute lymphoblastic leukemia drug sensitivity by changes in impedance via stromal cell adherence.
    PLoS One. 2021;16:e0258140.
    PubMed         Abstract available

  56. BAO F, Zhang L, Pei X, Lian C, et al
    MiR-20a-5p functions as a potent tumor suppressor by targeting PPP6C in acute myeloid leukemia.
    PLoS One. 2021;16:e0256995.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.